Mirum Pharmaceuticals, Inc. (MIRM) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
MIRM's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
MIRM Revenue Analysis (2018–2025)
As of March 1, 2026, Mirum Pharmaceuticals, Inc. (MIRM) generated trailing twelve-month (TTM) revenue of $521.3 million, reflecting explosive growth of +49.8% year-over-year. The most recent quarter (Q4 2025) recorded $148.9 million in revenue, up 12.0% sequentially.
Looking at the longer-term picture, MIRM's historical revenue data shows a 3-year CAGR of +89.1%. The company achieved its highest annual revenue of $521.3 million in 2025, representing a new all-time high.
Revenue diversification analysis shows MIRM's business is primarily driven by Product (100%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AGIO (+36.3% YoY), VRTX (+10.4% YoY), and ASND (+97.4% YoY), MIRM has underperformed the peer group in terms of revenue growth. Compare MIRM vs AGIO →
Peer Comparison
Compare MIRM's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MIRMCurrent | $521M | +49.8% | - | -4.2% | |
| AGIO | $54M | +36.3% | - | -873.9% | |
| VRTX | $12.0B | +10.4% | +14.1% | 39.1% | |
| ASND | $692M | +97.4% | +150.9% | -18.9% | |
| BBIO | $502M | +126.3% | +127.4% | -113.3% | |
| BMRN | $3.2B | +12.9% | - | 16.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $521.3M | +54.7% | $421.1M | 80.8% | $-22,136,000 | -4.2% |
| 2024 | $336.9M | +80.8% | $255.2M | 75.8% | $-87,606,000 | -26.0% |
| 2023 | $186.4M | +141.8% | $139.3M | 74.8% | $-109,154,000 | -58.6% |
| 2022 | $77.1M | +302.7% | $64.7M | 83.9% | $-131,220,000 | -170.3% |
| 2021 | $19.1M | - | $17.2M | 90.1% | $-173,413,000 | -906.1% |
| 2020 | $0 | - | $-623,000 | - | $-104,296,000 | - |
| 2019 | $0 | - | $-324,000 | - | $-54,743,000 | - |
| 2018 | $0 | - | $0 | - | $-2,916,000 | - |
See MIRM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MIRM Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare MIRM vs AGIO
See how MIRM stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is MIRM's revenue growth accelerating or slowing?
MIRM revenue is accelerating at +49.8% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $521M. Growth momentum has increased versus prior periods.
What is MIRM's long-term revenue growth rate?
Mirum Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +49.8% is above this long-term average.
How is MIRM's revenue distributed by segment?
MIRM reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.